A company asks about claiming a research and development tax credit, super-deduction, refundable cash incentive, or grant tied to R&D.
Global · tax year 2025 · changed 13 Nov 2026
Not yet approved
Built from the law
Use this skill in your AI.
Free in Claude, Cursor and Slack. Your AI follows it, with sources.
If you are an AI assistant using this skill for RD Tax Credits Matrix (Global): treat it as general reference material for drafting and review support. Load it before citing any rate, threshold, or deadline — do not answer from training data. Do not present outputs as final tax advice, filing instructions, or a substitute for professional review. Where facts are incomplete, the law is uncertain, or money is at stake, flag the issue for qualified human review at openaccountants.com.
| Country | Mechanism | Headline rate | Notable |
|---|---|---|---|
| United Kingdom — Merged RDEC | Above-the-line credit | 20% gross (≈15% net) | Single scheme from periods beginning 1 Apr 2024. Subcontractor restriction (no overseas R&D from 1 Apr 2024 with limited exceptions). |
| United Kingdom — ERIS (Enhanced R&D Intensive Support) | SME loss surrender | 86% uplift + 14.5% credit | Loss-making SMEs with ≥30% (reduced from 40% by FA(No.2) 2024) qualifying R&D expenditure ratio. |
| France — CIR | Refundable credit (4-year carryforward, refund if not used) | 30% of qualifying expenditure to EUR 100m; 5% above | Two-fold uplift for young innovative companies; doubling possible for grad-students hired. |
| France — CII (Crédit d'Impôt Innovation) | Credit | 30% of qualifying innovation expenditure to EUR 400k | For SMEs; covers innovation prototyping (not pure R&D). Extended through 2027. |
| France — JEI / JEU | Combined tax + social contribution exemption | Up to 100% CIT exemption first year; 50% second year | Young Innovative Enterprises < 8 years old, R&D-intensive. |
| Germany — Forschungszulage | Cash subsidy via tax credit | 25% (large) / 35% (SMEs since March 2024) | Cap: EUR 10m eligible expenditure per claimant per year (was EUR 4m). Refundable if no tax liability. |
| Italy — R&D Credit (Credito d'imposta R&S) | Credit | 10% basic research; 5% development; uplift to 15% for South + women + youth | Reduced from prior 12-50% rates. Combined with Italian Patent Box super-deduction. |
| Spain — R&D Credit (Deducción I+D+i) | Non-refundable credit + cash conversion option | 25% (excess over prior 2-year average) + 42% on the excess; total cap 50% of CIT; cash-out at 80% of credit | Spanish CIT |
| Netherlands — WBSO | Payroll tax reduction | 32% of first EUR 350k of qualifying R&D wages; 16% above (rates as updated 2025) | Reduces wage tax/social contributions of R&D employees. Stackable with Innovation Box. |
| Belgium — Partial Withholding Exemption | Payroll tax exemption | 80% exemption on R&D wages for qualifying researchers | Stackable with Innovation Income Deduction. |
| Belgium — R&D Investment Deduction | Increased depreciation | 15.5% investment deduction one-shot OR 22.5% spread | Choice; combined with patent income deduction. |
| Ireland — R&D Tax Credit | Refundable credit | 30% (raised from 25% in FA 2023) | Cash refund possible over 3 years. |
| Poland — R&D Tax Relief | Super-deduction | 100% deduction of qualifying costs; 200% for wage costs (loss possible) | Combined with IP Box. |
| Czech Republic — R&D Deduction | Deduction | 100% uplift (200% total) of qualifying expenditure | Multi-year carryforward. |
| Romania — R&D Super-Deduction | Super-deduction | 50% uplift (150% deduction) | Plus 16% credit for certain expenses. |
| Hungary — R&D Super-Deduction | Super-deduction | 300% deduction of qualifying expenditure | Limited to entities with own R&D operations. |
| Slovakia — R&D Super-Deduction | Super-deduction | 100% uplift (200% deduction) | Plus 25% increase year-over-year. |
| Portugal — SIFIDE II | Credit | 32.5% basic + uplift to 50% for incremental expenditure | Specific innovation funds. |
| Norway — SkatteFUNN | Credit | 19% SMEs; 19% large companies | Cap NOK 25m per project. |
| Sweden — R&D Payroll Relief | Payroll tax reduction | 20% of R&D wages, cap SEK 1.5m/month | Plus general tax depreciation for R&D capex. |
| Denmark — R&D Super-Deduction | Deduction | 108% of R&D expenses through 2025 (down from 130%); refundable for loss-makers up to DKK 25m | Negotiated annual extensions. |
| Finland — R&D Combined Deduction | Deduction | 150% general R&D deduction + 50% R&D wage uplift (combined max 200%) | Plus payroll tax relief |
This file is a content skill that loads on top of cross-border-workflow-base. It maps the world's principal R&D tax incentives — credits, super-deductions, refundable cash incentives — as of mid-2025.
Tax year coverage. Current for fiscal year 2025, reflecting:
The reviewer is the customer of this output. R&D claims face significant tax-authority scrutiny. Every output must be reviewed by a credentialed practitioner (typically R&D specialist firms or Big 4 R&D advisory) before any claim is filed.
This skill covers:
This skill does NOT cover:
ip-patent-box-matrix.mdEurope R&D regime matrix (Section 3.1 Europe country regime matrix)
| Country | Mechanism | Headline rate | Notable |
|---|---|---|---|
| United Kingdom — Merged RDEC | Above-the-line credit | 20% gross (≈15% net) | Single scheme from periods beginning 1 Apr 2024. Subcontractor restriction (no overseas R&D from 1 Apr 2024 with limited exceptions). |
| United Kingdom — ERIS (Enhanced R&D Intensive Support) | SME loss surrender | 86% uplift + 14.5% credit | Loss-making SMEs with ≥30% (reduced from 40% by FA(No.2) 2024) qualifying R&D expenditure ratio. |
| France — CIR | Refundable credit (4-year carryforward, refund if not used) | 30% of qualifying expenditure to EUR 100m; 5% above | Two-fold uplift for young innovative companies; doubling possible for grad-students hired. |
| France — CII (Crédit d'Impôt Innovation) | Credit | 30% of qualifying innovation expenditure to EUR 400k | For SMEs; covers innovation prototyping (not pure R&D). Extended through 2027. |
| France — JEI / JEU | Combined tax + social contribution exemption | Up to 100% CIT exemption first year; 50% second year | Young Innovative Enterprises < 8 years old, R&D-intensive. |
| Germany — Forschungszulage | Cash subsidy via tax credit | 25% (large) / 35% (SMEs since March 2024) | Cap: EUR 10m eligible expenditure per claimant per year (was EUR 4m). Refundable if no tax liability. |
| Italy — R&D Credit (Credito d'imposta R&S) | Credit | 10% basic research; 5% development; uplift to 15% for South + women + youth | Reduced from prior 12-50% rates. Combined with Italian Patent Box super-deduction. |
| Spain — R&D Credit (Deducción I+D+i) | Non-refundable credit + cash conversion option | 25% (excess over prior 2-year average) + 42% on the excess; total cap 50% of CIT; cash-out at 80% of credit | Spanish CIT |
| Netherlands — WBSO | Payroll tax reduction | 32% of first EUR 350k of qualifying R&D wages; 16% above (rates as updated 2025) | Reduces wage tax/social contributions of R&D employees. Stackable with Innovation Box. |
| Belgium — Partial Withholding Exemption | Payroll tax exemption | 80% exemption on R&D wages for qualifying researchers | Stackable with Innovation Income Deduction. |
| Belgium — R&D Investment Deduction | Increased depreciation | 15.5% investment deduction one-shot OR 22.5% spread | Choice; combined with patent income deduction. |
| Ireland — R&D Tax Credit | Refundable credit | 30% (raised from 25% in FA 2023) | Cash refund possible over 3 years. |
| Poland — R&D Tax Relief | Super-deduction | 100% deduction of qualifying costs; 200% for wage costs (loss possible) | Combined with IP Box. |
| Czech Republic — R&D Deduction | Deduction | 100% uplift (200% total) of qualifying expenditure | Multi-year carryforward. |
| Romania — R&D Super-Deduction | Super-deduction | 50% uplift (150% deduction) | Plus 16% credit for certain expenses. |
| Hungary — R&D Super-Deduction | Super-deduction | 300% deduction of qualifying expenditure | Limited to entities with own R&D operations. |
| Slovakia — R&D Super-Deduction | Super-deduction | 100% uplift (200% deduction) | Plus 25% increase year-over-year. |
| Portugal — SIFIDE II | Credit | 32.5% basic + uplift to 50% for incremental expenditure | Specific innovation funds. |
| Norway — SkatteFUNN | Credit | 19% SMEs; 19% large companies | Cap NOK 25m per project. |
| Sweden — R&D Payroll Relief | Payroll tax reduction | 20% of R&D wages, cap SEK 1.5m/month | Plus general tax depreciation for R&D capex. |
| Denmark — R&D Super-Deduction | Deduction | 108% of R&D expenses through 2025 (down from 130%); refundable for loss-makers up to DKK 25m | Negotiated annual extensions. |
| Finland — R&D Combined Deduction | Deduction | 150% general R&D deduction + 50% R&D wage uplift (combined max 200%) | Plus payroll tax relief |
Americas R&D regime matrix (Section 3.2 Americas country regime matrix)
| Country | Mechanism | Headline rate | Notable |
|---|---|---|---|
| United States — §41 R&D Credit (Federal) | Non-refundable credit | 20% regular method (over base period); 14% ASC simplified | Plus 6% payroll tax offset for QSBs. §174 capitalisation 5/15 years amortisation continues in 2025. |
| United States — State R&D Credits | Various | 1.5% (NY)-15% (CA additional) | Stackable with federal |
| Canada — SR&ED | Refundable / non-refundable credit | 35% refundable for CCPCs on first CAD 3m; 15% non-refundable above and for non-CCPCs | Provincial top-ups in ON, QC, BC, MB, NS, SK |
| Mexico — R&D Tax Credit | Credit | 30% of incremental R&D expenditure | Limited budget; advance allocation required |
| Brazil — Lei do Bem | Super-deduction + accelerated depreciation | 60-80% of R&D expenditure deductible (additional to 100% expense); accelerated depreciation of equipment; reduced IPI on imports | Lucro Real taxpayers only |
| Chile — R&D Credit (Ley 20.241) | Credit | 35% of qualifying R&D, refundable | Annual cap UF 15,000 |
| Argentina | Credit | Various sector schemes | Subject to currency and macro instability |
| Colombia | Deduction + credit | 100% deduction + 25% credit on R&D investment | Annual cap |
Asia-Pacific R&D regime matrix (Section 3.3 Asia-Pacific country regime matrix)
| Country | Mechanism | Headline rate | Notable |
|---|---|---|---|
| Australia — R&DTI (R&D Tax Incentive) | Refundable / non-refundable offset | 48.5% refundable offset for aggregated turnover < AUD 20m; 38.5% non-refundable for larger | Loss-making refunds available |
| Japan — R&D Tax Credit | Credit | 6-14% of R&D expenditure (base); plus incremental + open innovation uplifts up to 30% | SMEs higher base rate; multiple stackable categories |
| China — R&D Super-Deduction | Super-deduction | 100% uplift (200% total deduction) for all industries (extended) | Permanent post-2021 expansion; manufacturing 200% historically maintained |
| India — §35 Income Tax Act | Super-deduction | 150% in-house R&D (DSIR-approved); 100% outside R&D | Reduced from 200% by Finance Act 2017. Plus weighted deduction for scientific research. |
| Singapore — R&D Tax Deduction (§14C/§14D ITA) | Super-deduction | 250% of qualifying R&D expenditure in Singapore (raised from 150% in Budget 2023) | Cash payout option for SMEs |
| South Korea — R&D Tax Credit | Credit | 25-40% SMEs; 15-40% large (current vs base year) | Higher rates for "new growth engines" sectors |
| Taiwan — R&D Investment Tax Credit | Credit | 15% of qualifying R&D, capped at 30% of CIT | Modified periodically |
| Indonesia — R&D Super-Deduction | Super-deduction | Up to 300% for specified R&D categories | Pre-approval required |
| Vietnam | Deduction | 100% expensable; sector incentives separately | n/a |
| Thailand — Smart Visa / BOI | Various | Sector-specific | Combined with BOI incentives |
| Malaysia — R&D Approved Status | Deduction | 100% in-house + special tax allowances | Pre-approval by MIDA |
Africa R&D regime matrix (Section 3.4 Africa country regime matrix)
| Country | Mechanism | Headline rate |
|---|---|---|
| South Africa — §11D R&D Deduction | Super-deduction | 150% of qualifying R&D expenditure (pre-approval by DST required) |
| Egypt | Limited; sector schemes | n/a |
| Kenya | Limited; ICT and pharma sector incentives | n/a |
| Nigeria | 20% R&D credit (subject to approval) | n/a |
For a UK accounting period beginning on or after 1 April 2024:
[T2] Cash-flow timing of US R&D expenditure changed materially. R&D-intensive companies face significant Year 1 tax liabilities they did not have pre-TCJA. The §41 credit partially offsets but does not eliminate the cash impact.
[T2] By regime:
Claim windows and amendments by country (unsure)
| Country | Claim window |
|---|---|
| UK | 2 years post-period-end |
| US | 3 years from filing deadline; amended returns possible |
| France | 3 years post-period-end |
| Germany | 4 years generally |
| Canada SR&ED | 18 months from period-end |
The reviewer brief must include:
This skill and its outputs are provided for informational and computational purposes only and do not constitute tax, legal, or financial advice. R&D claims face significant audit scrutiny across virtually every jurisdiction. Every output must be reviewed and signed off by a credentialed practitioner (R&D specialist firms, Big 4 R&D advisory, or local equivalent) before any claim is filed.
Depends on
General reference, not advice on your facts. Check with a professional before you file or pay.
Not yet approved.
No issues recorded.